Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis

Nature Reviews Rheumatology

Volumn 7, Issue 11, 2011, Pages 664-675

  Robinson, Angela B ^a   Reed, Ann M ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; AZATHIOPRINE; BETA INTERFERON; CD123 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; CD83 ANTIGEN; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NEOPTERIN; PLACEBO; RITUXIMAB; VON WILLEBRAND FACTOR;

ADRENAL INSUFFICIENCY; ADULT DISEASE; AGE; AVASCULAR NECROSIS; CALCINOSIS; CATARACT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL PROTOCOL; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DYSPHAGIA; FEVER; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTERFERON REGULATORY FACTOR 5 GENE; INTERSTITIAL LUNG DISEASE; LETHARGY; LIPODYSTROPHY; MICROCHIMERISM; MOLECULAR PATHOLOGY; MUSCLE WEAKNESS; MYOCARDITIS; OSTEOPOROSIS; PATIENT ASSESSMENT; PERICARDITIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PTPN22 GENE; RASH; REVIEW; SIDE EFFECT; TUMOR NECROSIS FACTOR GENE; VOMITING; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ADULT; CHILD; DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 80455177000     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.139     Document Type: Review

References (164)

1. Rider, L. G. & Miller, F. W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. N. Am. 23, 619-655 (1997).
2. Mammen, A. L. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann. NY Acad. Sci. 1184, 134-153 (2010).
3. Bitnum, S., Daeschner, C. W. Jr, Travis, L. B., Dodge, W. F. & Hopps, H. C. Dermatomyositis. J. Pediatr. 64, 101-131 (1964).
4. Ravelli, A. et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 62, 63-72 (2010).
5. Dankó, K., Ponyi, A., Constantin, T., Borgulya, G. & Szegedi, G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 83, 35-42 (2004).
6. Mendez, E. P. et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Care Res. 49, 300-305 (2003).
7. Oddis, C. V., Conte, C. G., Steen, V. D. & Medsger, T. A. Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J. Rheumatol. 17, 1329-1334 (1990).
8. Vargas-Leguas, H. et al. Polymyositis-dermatomyositis: incidence in Spain (1997-2004).Med. Clin. (Barc.) 129, 721-724 (2007).
9. Cox, S., Limaye, V., Hill, C., Blumbergs, P. & Roberts-Thomson, P. Idiopathic inflammatory myopathies: diagnostic criteria, classification and epidemiological features. Int. J. Rheum. Dis. 13, 117-124 (2010).
10. Guseinova, D. et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin. Exp. Rheumatol. 29, 117-124 (2011).
11. Mathiesen, P. R., Zak, M., Herlin, T. & Nielsen, S. M. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. Clin. Exp. Rheumatol. 28, 782-789 (2010).
12. Sato, J. O. et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin. Exp. Rheumatol. 27, 1031-1038 (2009).
13. Rider, L. G. & Miller, F. W. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305, 183-190 (2011).
14. Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis. N. Engl. J. Med. 292, 344-347 (1975).
15. Tomasova Studynkova, J., Charvat, F., Jarosova, K. & Vencovsky, J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology 46, 1174-1179 (2007).
16. Lopez de Padilla, C. M., Vallejo, A. N., Lacomis, D., McNallan, K. & Reed, A. M. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 60, 1160-1172 (2009).
17. Ostrowski, R. A., Sullivan, C. L., Seshadri, R., Morgan, G. A. & Pachman, L. M. Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. Arthritis Rheum. 62, 1533-1538 (2010).
18. Stringer, E., Singh-Grewal, D. & Feldman, B. M. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 58, 3585-3592 (2008).
19. Rider, L. G. et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthriti Rheum. 60, 3425-3435 (2009).
20. Horowitz, M., McNeil, J. D., Maddern, G. J., Collins, P. J. & Shearman, D. J. Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis. Gastroenterology 90, 434-439 (1986).
21. Fathi, M., Lundberg, I. E. & Tomling, G. Pulmonary complications of polymyositis and dermatomyositis. Semin. Respir. Crit. Care Med. 28, 451-458 (2007).
22. Lowry, C. A. & Pilkington, C. A. Juvenile dermatomyositis: extramuscular manifestations and their management. Curr. Opin. Rheumatol. 21, 575-580 (2009).
23. Oliveri, M. B., Palermo, R., Mautalen, C. & Hubscher, O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J. Rheumatol. 23, 2152-2155 (1996).
24. Bowyer, S. L., Blane, C. E., Sullivan, D. B. & Cassidy, J. T. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J. Pediatr. 103, 882-888 (1983).
25. Eidelman, N. et al. Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Res. Ther. 11, R159 (2009).
26. Huemer, C. et al. Lipodystrophy in patients with juvenile dermatomyositis-evaluation of clinical and metabolic abnormalities. J. Rheumatol. 28, 610-615 (2001).
27. Lee, L. A. & Hobbs, K. F. Lipodystrophy and metabolic abnormalities in a case of adult dermatomyositis. J. Am. Acad. Dermatol. 57, S85-S87 (2007).
28. Marie, I. et al. Short term and long term outcome of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. http:dx.doi.org/10.1002/art.30513
29. Sanner, H. et al. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann. Rheum. Dis. 70, 86-91 (2011).
30. Connors, G. R., Christopher-Stine, L., Oddis, C. V. & Danoff, S. K. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138, 1464-1474 (2010).
31. Sato, S.et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571-1576 (2005).
32. Schwartz, T., Sanner, H., Husebye, T., Flato, B. & Sjaastad, I. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann. Rheum. Dis. 70, 766-771 (2011).
33. Lundberg, I. E. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 45 (Suppl. 4), iv18-iv21 (2006).
34. Santos, M. J. & Fonseca, J. E. Metabolic syndrome, inflammation and atherosclerosis-the role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol. Port. 34, 590-598 (2009).
35. Klein, R. Q., Teal, V., Taylor, L., Troxel, A. B. & Werth, V. P. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J. Am. Acad. Dermatol. 57, 937-943 (2007).
36. Sato, S. & Kuwana, M. Clinically amyopathic dermatomyositis. Curr. Opin. Rheumatol. 22, 639-643 (2010).
37. Nagai, Y., Mizuno, T., Yoshizawa, C. & Ishikawa, O. Fatal interstitial pneumonia in juvenile dermatomyositis. Eur. J. Dermatol. 20, 208-210 (2010).
38. Abe, Y. et al. Juvenile amyopathic dermatomyositis complicated by progressive interstitial pneumonia. Pediatr. Int. 52, 149-153 (2010).
39. Azuma, K. et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis, and clinically amyopathic dermatomyositis. Mod. Rhematol. 21, 178-183 (2010).
40. Morris, P. & Dare, J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J. Pediatr. Hematol. Oncol. 32, 189-191 (2010).
41. Sigurgeirsson, B., Lindelof, B., Edhag, O. & Allander, E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N. Engl. J. Med. 326, 363-367 (1992).
42. Zahr, Z. A. & Baer, A. N. Malignancy in myositis. Curr. Rheumatol. Rep. 13, 208-215 (2011).
43. Guzman, J., Petty, R. E. & Malleson, P. N. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J. Rheumatol. 21, 739-743 (1994).
44. Vancsa, A. et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 77, 125-130 (2010).
45. Wedderburn, L. R. et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 46, 1786-1791 (2007).
46. DeBenedetti, F., DeAmici, M., Aramini, L., Ruperto, N. & Martini, A. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch. Dis. Child. 69, 232-235 (1993).
47. Rider, L. G. et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin. Chem. 48, 1681-1688 (2002).
48. Bilgic, H. et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 60, 3436-3446 (2009).
49. Parodi, A. et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms, and circulating antibodies. Acta Derm. Venereol. 82, 48-51 (2002).
50. Brouwer, R. et al. Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis. 60, 116-123 (2001).
51. Mahler, M. & Raijmakers, R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun. Rev. 6, 432-437 (2007).
52. Ranque, B. et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand. J. Rheumatol. 39, 498-505 (2010).
53. Wedderburn, L. R. & Rider, L. G. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract. Res. Clin. Rheumatol. 23, 665-678 (2009).
54. Imbert-Masseau, A., Hamidou, M., Agard, C., Grolleau, J. Y. & Cherin, P. Antisynthetase syndrome. Joint Bone Spine 70, 161-168 (2003).
55. Gunawardena, H. et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 47, 324-328 (2008).
56. Gunawardena, H. et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 60, 1807-1814 (2009).
57. Kaji, K. et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46, 25-28 (2007).
58. Espada, G., Maldonado Cocco, J. A., Fertig, N. & Oddis, C. V. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J. Rheumatol. 36, 2547-2551 (2009).
59. Khanna, S. & Reed, A. M. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 41, 581-592 (2010).
60. Pachman, L. M., Jonasson, O., Cannon, R. A. & Friedman, J. M. Increased frequency of HLA-B8 in juvenile dermatomyositis. Lancet 2. 1238 (1977).
61. Mamyrova, G. et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 54, 3979-3987 (2006).
62. Reed, A. M. & Stirling, J. D. The HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum. Immunol. 44, 131-135 (1995).
63. Reed, A. M., Pachman, L. & Ober, C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1*0501. Hum. Immunol. 32, 235-240 (1991).
64. Wagner, M. S., McNallan, K. T., Crowson, C. S. & Reed, A. M. Discriminating functional variants in the IFN-inducible pathway in JDM and JIA. Arthritis Rheum. 58 (Suppl.), S499-S500 (2008).
65. Pachman, L. M. et al. TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum. 43, 2368-2377 (2000).
66. Chinoy, H. et al. Tumor necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology 46, 1411-1416 (2007).
67. Mamyrova, G. et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 58, 3941-3950 (2008).
68. Chinoy, H. et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum. 58, 3247-3254 (2008).
69. Miles, L. et al. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum. 17, 725-730 (2007).
70. Pestronk, A., Schmidt, R. E. & Choksi, R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 42, 53-61 (2010).
71. Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343-356 (1990).
72. Bohan, A., Peter, J. B., Bowman, R. L. & Pearson, C. M. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56, 255-286 (1977).
73. Wang, Y. J. et al. Juvenile and adult dermatomyositis among the Chinese: a comparative study. Zhonghua Yi Xue Za Zhi (Taipei) 52, 285-292 (1993).
74. Lopez de Padilla, C. M. et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 56, 1658-1668 (2007).
75. De Bleecker, J. L., Engel, A. G. & Butcher, E. C. Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromuscul. Disord. 6, 255-260 (1996).
76. Van der Pas, J. Hengstman, G. J., ter Laak, H. J., Borm, G. F. & van Engelen, B. G. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry 75, 136-139 (2004).
77. Li, C. K. et al. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J. Rheumatol. 31, 605-609 (2004).
78. Nagaraju, K. Role of major histocompatibility complex class I molecules in autoimmune myositis. Curr. Opin. Rheumatol. 17, 725-730 (2005).
79. Greenberg, S. A. et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65, 1782-1787 (2005).
80. Chevrel, G. et al. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J. Neuroimmunol. 137, 125-133 (2003).
81. Page, G., Chevrel, G. & Miossec, P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum. 50, 199-208 (2004).
82. Tournadre, A. et al. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 46, 297-301 (2009).
83. Englund, P., Nennesmo, I., Klareskog, L. & Lundberg, I. E. Interleukin-1α expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 46, 1044-1055 (2002).
84. Sallum, A. M. et al. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun. Rev. 5, 93-100 (2006).
85. Lundberg, I., Kratz, A., Alexanderson, H. & Patarroyo, M. Decreased expression of interleukin-1α, interleukin-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 43, 336-348 (2000).
86. Shrestha, S. et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 62, 2813-2822 (2010).
87. Nagaraju, K. et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52, 1824-1835 (2005).
88. Grimley, P. M. et al. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab. Invest. 52, 638-649 (1985).
89. Kuyama, J. et al. Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon. Ultrastuct. Pathol. 10, 77-85 (1986).
90. Feldman, D., Goldstein, A. L., Cox, D. C. & Grimley, P. M. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2', 5' oligoadenylate synthetase formation. Lab. Invest. 58, 584-589 (1988).
91. Tateyama, M. et al. Expression of tumor necrosis factor-α in muscles of polymyositis. J. Neurol. Sci. 146, 45-51 (1997).
92. Loell, I. et al. Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies-evident in chronic but not in untreated newly diagnosed patients. Clin. Physiol. Funct. Imaging 31, 18-25 (2011).
93. Grundtman, C. et al. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum. 56, 674-687 (2007).
94. Ishii, W. et al. Flow cytometric analysis of lymphocyte subpopulation and Th1/Th2 balance in patients with polymyositis and dermatomyositis. Intern. Med. 47, 1593-1599 (2008).
95. Eisenstein, D. M., O'Gorman, M. R. & Pachman, L. M. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J. Rheumatol. 24, 1830-1832 (1997).
96. O'Gorman, M. R., Bianchi, L., Zaas, D., Corrochano, V. & Pachman, L. M. Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin. Diagn. Lab. Immunol. 7, 693-697 (2000).
97. Viguier, M. et al. Blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine 82, 82-86 (2003).
98. Reed, A. M., Shock, L. P. & Picornell, J. Chimerism in children with juvenile dermatomyositis. Lancet 356, 2156-2157 (2000).
99. Artlett, C. M. et al. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies: Childhood Myositis Heterogeneity Collaborative Group. Lancet 356, 2155-2156 (2000).
100. Reed, A. M., McNallan, K., Wettstein, P., Vehe, R. & Ober, C. Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? J. Immunol. 172, 5041-5046 (2004).
101. Stevens, A. M. Foreign cells in polymyositis: could stem cell transplantation and pregnancy-derived chimerism lead to the same disease? Curr. Rheumatol. Rep. 5, 437-444 (2003).
102. Manlhiot, C. et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology 47, 526-529 (2008).
103. Pachman, L. M. et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 53, 166-172 (2005).
104. Pachman, L. M. et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis Rheum. 38, 1513-1518 (1995).
105. Vegosen, L. J. et al. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum. 56, 2719-2728 (2007).
106. Love, L. A. et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 60, 2499-2504 (2009).
107. Ramanan, A. V. et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 52, 3570-3578 (2005).
108. Stringer, E. et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J. Rheum. 37, 1953-1961 (2010).
109. Miller, J., Walsh, Y. & Saminaden, S. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J. Neurol. Sci. 199 (Suppl. 1) S53 (2002).
110. Vencovsky, J. et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand. J. Rheumatol. 29, 95-102 (2000).
111. Villalba, L. et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 41, 392-399 (1998).
112. Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993-2000 (1993).
113. Marie, I. et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 62, 1748-1755 (2010).
114. Manlhiot, C. et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics 121, e626-e630 (2008).
115. Rouster-Stevens, K. A., Morgan, G. A., Wang, D. & Pachman, L. M. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res. 62, 1446-1451 (2010).
116. Dagher, R. et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol. Int. http://dx.doi.org/10.1007/s00296-010-1653-5.
117. Reiff, A. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J. Rheumatol. 24, 2436-2443 (1997).
118. Zeller, V., Cohen, P., Prieur, A. M. & Guillevin, L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J. Rheumatol. 23, 1424-1427 (1996).
119. Riley, P. et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47, 877-880 (2008).
120. Marco Puche, A., Calvo Penades, I. & Lopez Montesinos, B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin. Exp. Rheumatol. 28, 135-140 (2010).
121. Oliveri, M. B., Palermo, R., Mautalen, C. & Hubscher, O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J. Rheumatol 23, 2152-2155 (1996).
122. Vinen, C. S., Patel, S. & Bruckner, F. E. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford) 39, 333-334 (2000).
123. Rios Fernandez, R., Callejas Rubio, J. L., Sanchez Cano, D., Saez Moreno, J. A. & Ortego Centeno, N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin. Exp. Rheumatol. 27, 1009-1016 (2009).
124. Oddis, C. V. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM)-The RIM Study [abstract L13]. Arthritis Rheum. 62, 3844 (2010).
125. Huber, A. M. et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res. 62, 219-225 (2010).
126. Robinson, A. B. et al. Diagnostic evaluation and medication usage in a cohort of subjects with JDM from the CARRAnet Registry. Poster presented at the American College of Rheumatology Pediatric Rheumatology Symposium 2011.
127. Feldman, B. M., Rider, L. G., Reed, A. M. & Pachman, L. M. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 371, 2201-2212 (2008).
128. Martin, N. et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; The Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology 50, 137-145 (2007).
129. Miller, F. W. In Arthritis and Allied Conditions: A Textbook of Rheumatology 15th edn (eds Koopman, W. & Moreland, L) 1593-1620 (Lippincott Williams & Wilkins, Philadelphia, (2005).
130. Fardet, L. et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine 88, 91-97 (2009).
131. Ramanan, A. V. & Feldman, B. M. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum. Dis. Clin. North Am. 52, 493-520 (2005).
132. Selva-O'Callaghan, A. et al. Nailfold capillary microscopy in adults with inflammatory myopathy. Semin. Arthritis Rheum. 39, 398-404 (2010).
133. Na, S. J., Kim, S. M., Sunwoo, I. N. & Choi, Y. C. Clinical characteristics and outcomes of juvenile and adult dermatomyositis. J. Korean Med. Sci. 24, 715-721 (2009).
134. Huber, A. M. et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 43, 541-549 (2000).
135. Tse, S. et al. The arthritis of inflammatory childhood myositis syndromes. J. Rheumatol. 28, 192-197 (2001).
136. Parodi, A. et al. Dermatomyositis in 132 patients with different clinical subtypes: cutaneous signs, constitutional symptoms and circulating antibodies. Acta Derm. Venereol. 82, 48-51 (2002).
137. Kang, E. H. et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet. Disord. 11, 223 (2010).
138. O'Hanlon, T. P. et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 54, 3670-3681 (2006).
139. Yamasaki, Y. et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 54, 2004-2009 (2006).
140. Brouwer, R. et al. Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis. 60, 116-123 (2001).
141. Okada, S. et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 48, 2285-2293 (2003).
142. Hoshino, K. et al. Anti-MDA5 and anti-TIF1-? antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49, 1726-1733 (2010).
143. Kaji, K. et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46, 25-28 (2007).
144. Nakashima, R. et al. The RIG-1-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49, 433-440 (2010).
145. Hausmanowa-Petrusewicz, I. et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 40, 1257-1266 (1997).
146. Iannone, F. et al. T-lymphocyte immunophenotyping in polymyositis and dermatomyositis. Br. J. Rheumatol. 35, 839-845 (1996).
147. Jain, A. et al. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch. Pathol. Lab. Med. 131, 1070-1076 (2007).
148. Wedderburn, L. R. et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 57, 1192-1201 (2007).
149. + T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome. Clin. Exp. Immunol. 137, 189-194 (2004).
150. Choi, J. H. et al. Differential immunohistological features of inflammatory myopathies and dysferlinopathy. J. Korean Med. Sci. 24, 1015-1023 (2009).
151. + lymphocytes in dermatomyositis. Clin. Exp. Dermatol. 31, 576-581 (2006).
152. + T regulatory cells in idiopathic inflammatory myopathies. J. Neuroimmunol. 225, 137-142 (2010).
153. Antiga, E. et al. Characterization of regulatory T cells in patients with dermatomyositis. J. Autoimmun. 35, 342-350 (2010).
154. Crowe, W. E., Bove, K. E., Levinson, J. E. & Hilton, P. K. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 25, 126-139 (1982).
155. Kissel, J. T., Mendell, J. R. & Rammohan, K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314, 329-334 (1986).
156. Jain, A. et al. Detection of the membrane attack complex as a diagnostic tool in dermatomyositis. Acta Neurol. Scand. 123, 122-129 (2011).
157. Grundtman, C. et al. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum. 56, 674-687 (2007).
158. Fedczyna, T. O., Lutz, J. & Pachman, L. M. Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFα-308A allele. Clin. Immunol. 100, 236-239 (2001).
159. Hassan, A. B., Fathi, M., Dastmalchi, M., Lundberg, I. E. & Padyukov, L. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J. Autoimmun. 27, 62-68 (2006).
160. Chinoy, H. et al. Clinical, serological and HLA profiles in non-Caucasian UK idiopathic inflammatory myopathy. Rheumatology (Oxford) 48, 591-592 (2009).
161. O'Hanlon, T. P. et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. Medicine (Baltimore) 84, 338-349 (2005).
162. Chinoy, H. et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res. Ther. 8, R13 (2006).
163. Pachman, L. M., Fedczyna, T. O., Lechman, T. S. & Lutz, J. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr. Rheumatol. Rep. 3, 379-386 (2001).
164. Werth, V. P., Callen, J. P., Ang, G. & Sullivan, K. E. Associations of tumor necrosis factor α and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J. Invest. Dermatol. 119, 617-620 (2002).